Unmasking a Case of Asymptomatic Charcot-Marie-Tooth Disease (CMT1A) With Vincristine

Charcot-Marie-Tooth (CMT) disease is a hereditary demyelinating disease of the peripheral nervous system that results in sensory and motor dysfunction. CMT includes a spectrum of diseases with different types of mutations in the genes encoding myelin protein, resulting in a variety of dysfunctions i...

সম্পূর্ণ বিবরণ

সংরক্ষণ করুন:
গ্রন্থ-পঞ্জীর বিবরন
প্রধান লেখক: Roopam Jariwal MS (Author), Basel Shoua MD (Author), Katayoun Sabetian MD (Author), Piruthiviraj Natarajan MD (Author), Everardo Cobos MD (Author)
বিন্যাস: গ্রন্থ
প্রকাশিত: SAGE Publishing, 2018-02-01T00:00:00Z.
বিষয়গুলি:
অনলাইন ব্যবহার করুন:Connect to this object online.
ট্যাগগুলো: ট্যাগ যুক্ত করুন
কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_ca9a18a47aa648d2aec0ff70c24ab3b1
042 |a dc 
100 1 0 |a Roopam Jariwal MS  |e author 
700 1 0 |a Basel Shoua MD  |e author 
700 1 0 |a Katayoun Sabetian MD  |e author 
700 1 0 |a Piruthiviraj Natarajan MD  |e author 
700 1 0 |a Everardo Cobos MD  |e author 
245 0 0 |a Unmasking a Case of Asymptomatic Charcot-Marie-Tooth Disease (CMT1A) With Vincristine 
260 |b SAGE Publishing,   |c 2018-02-01T00:00:00Z. 
500 |a 2324-7096 
500 |a 10.1177/2324709618758349 
520 |a Charcot-Marie-Tooth (CMT) disease is a hereditary demyelinating disease of the peripheral nervous system that results in sensory and motor dysfunction. CMT includes a spectrum of diseases with different types of mutations in the genes encoding myelin protein, resulting in a variety of dysfunctions in its life cycle. In CMT subtype 1A there is duplication mutation of peripheral myelin protein 22 gene on chromosome 17. Incomplete penetrance, gene-dosage effect, and variable expressivity can attribute to the asymptomatic nature of the disease in some subset of patients. Vincristine administration is contraindicated in patients who are alrea\dy diagnosed with CMT disease. We report a case of asymptomatic CMT disease unmasked only by the neurotoxic effects of vincristine. Genetic testing for a patient with a preexisting family background of inherited diseases before starting vincristine therapy can potentially prevent a disability. 
546 |a EN 
690 |a Medicine (General) 
690 |a R5-920 
690 |a Pathology 
690 |a RB1-214 
655 7 |a article  |2 local 
786 0 |n Journal of Investigative Medicine High Impact Case Reports, Vol 6 (2018) 
787 0 |n https://doi.org/10.1177/2324709618758349 
787 0 |n https://doaj.org/toc/2324-7096 
856 4 1 |u https://doaj.org/article/ca9a18a47aa648d2aec0ff70c24ab3b1  |z Connect to this object online.